$0.941 0.0 0.0%
Last Trade - 01/12/20
| Market Cap | £n/a |
| Enterprise Value | £n/a |
| Revenue | £n/a |
| Position in Universe | th / 7245 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | June 13, 2013 |
| Public Since | March 29, 2017 |
| No. of Shareholders: | 230 |
| No. of Employees: | 5 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 23,790,667 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 1185 Avenue of the Americas Fl 3, NEW YORK, 10036-2600, United States |
| Web | |
| Phone | +1 973 2420005 |
| Auditors | Friedman LLP |
As of 01/12/20, shares in Neurotrope Inc are trading at $0.941, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.
Shares in Neurotrope Inc are currently trading at $0.941 and the price has moved by 3.68% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Neurotrope Inc price has moved by -20.54% over the past year.
Of the analysts with advisory recommendations for Neurotrope Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Neurotrope Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Neurotrope Inc is scheduled to issue upcoming financial results on the following dates:
Neurotrope Inc does not currently pay a dividend.
Neurotrope Inc does not currently pay a dividend.
Neurotrope Inc does not currently pay a dividend.
To buy shares in Neurotrope Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Neurotrope Inc are currently trading at $0.941, giving the company a market capitalisation of £n/a.
Here are the trading details for Neurotrope Inc:
We were not able to load our ranking data for Neurotrope Inc
We were not able to load any forecast data for Neurotrope Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurotrope Inc. Over the past six months, the relative strength of its shares against the market has been -40.8%. At the current price of $0.941, shares in Neurotrope Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Neurotrope Inc.
We were unable to find the directors for Neurotrope Inc.
Here are the top five shareholders of Neurotrope Inc based on the size of their shareholding:
